The proneural GBM cohort showed significantly improved prognosis as compared with patients with other subtypes (Verhaak et al., 2010) but failed to respond to immunotherapy as efficiently as the mesenchymal GBM cohort, presumably owing to TGF-R2 deficiency (Beier et al., 2012). The gene discussed is TGFBR2; the disease is glioblastoma.